Association of Mitochondrial ribosomal protein S33 expression with poor prognosis in glioma

Despite advancements in diagnostic and therapeutic strategies, early detection and improved prognosis of gliomas remain challenging. A deeper understanding of glioma pathogenesis and the identification of reliable biomarkers are crucial for early diagnosis and the reduction of healthcare costs. Mitochondrial ribosomal protein S33 (MRPS33), a key component of mitochondrial protein synthesis, has not been well-characterized in terms of its expression profile, prognostic significance, and immunological relevance in glioma. This study aims to elucidate these aspects through bioinformatics analyses utilizing data from The Cancer Genome Atlas, Genotype-Tissue Expression Project, and Tumor Immune Estimation Resource databases through the Sangerbox platform. Our results indicate a pronounced upregulation of MRPS33 in glioma tissues, which is significantly associated with poor prognosis, heightened immune cell infiltration, and differential drug sensitivities. Furthermore, functional enrichment analyses suggest that MRPS33 is intricately involved in several key biological processes, thereby underscoring its potential role in glioma pathophysiology. In conclusion, our findings support the potential of MRPS33 as a prognostic biomarker and therapeutic target in glioma, providing insights that may advance our understanding of disease mechanisms and inform future clinical strategies.